Compare DexCom, Inc. (DXCM) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs GE Vernova Inc — how do they compare? DexCom, Inc. trades at $90.29 (market cap $33.79B), while GE Vernova Inc trades at $1,040.49 (market cap $269.50B). The key difference: GE Vernova Inc is far larger — about 8× DexCom, Inc.'s market cap, and GE Vernova Inc pays a 0.2% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GEV | |
|---|---|---|
Market Cap | $33.79B | $269.50B |
Sector | Health | Technology |
52-Week High | $89.53 | $1.17K |
52-Week Low | $54.84 | $547.96 |
Enterprise Value | $33.24B | $259.17B |
Dividend Yield | — | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
GE Vernova (GEV) trades at $1,038.13, up 4.77% with strong bullish momentum. The stock shows robust fundamentals with 23% net income margin and 91% ROE, though valuation ratios appear elevated. Recent Q2 2026 earnings missed expectations, but the company maintains a massive $176 billion backlog and benefits from AI-driven power demand. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus remains strongly positive with 76% buy ratings.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, but premium valuation and execution risks on backlog conversion warrant caution. The stock offers growth exposure to power grid modernization with upside to the $1,270 consensus target, though investors should monitor quarterly execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
